NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults

Completed

Conditions: Normal Physiology

First Posted Date: 2012-11-21

Last Posted Date: 2019-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT01730144

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Genomics of Kidney Transplantation

Completed

Conditions: Kidney Transplant Donor
KidneyTransplant Recipients
Simultaneous Kidney/Pancreas Recipients

First Posted Date: 2012-10-26

Last Posted Date: 2017-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1552

Registration Number: NCT01714440

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦
University of Alberta, Edmonton, Alberta, Canada

and more 2 locations

Tdap Vaccine in Post-Partum Women

Phase 4

Completed

Conditions: Pertussis
Diphtheria
Tetanus

Interventions: Biological: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate

First Posted Date: 2012-10-22

Last Posted Date: 2017-05-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT01711645

Locations: 🇺🇸
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States

Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Vitamin D3 400 IU
Drug: Vitamin D3 6000 IU

First Posted Date: 2012-10-18

Last Posted Date: 2015-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7

Registration Number: NCT01709474

Locations: 🇺🇸
Lucile Packard Children's Hospital, Stanford University, Palo Alto, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 10 locations

Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV

Conditions: Papillomavirus Infections
Neoplasms, Squamous Cell

First Posted Date: 2012-10-18

Last Posted Date: 2012-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 165

Registration Number: NCT01709448

Locations: 🇺🇸
Cincinnati VA Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

Phase 2

Withdrawn

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Rituximab

First Posted Date: 2012-10-05

Last Posted Date: 2012-10-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01702038

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Seasonal Influenza DNA vaccine
Biological: TIV

First Posted Date: 2012-08-30

Last Posted Date: 2022-08-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 316

Registration Number: NCT01676402

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 1 locations

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)
Biological: Vaccine placebo (Leibovitz-15 [L-15])
Biological: A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)
Biological: 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
Biological: Vaccine placebo (FluMist®)

First Posted Date: 2012-08-28

Last Posted Date: 2015-12-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT01674205

Locations: 🇺🇸
University of Rochester Medical Center: Facility for Evaluation of Flu Vaccines, Rochester, New York, United States

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Moxifloxacin
Drug: PA-824
Other: Placebo

First Posted Date: 2012-08-28

Last Posted Date: 2014-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 74

Registration Number: NCT01674218

Locations: 🇺🇸
Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States

Fluorodeoxyglucose Imaging Studies to Detect Lymphoma

Withdrawn

Conditions: Lymphoma
Autoimmune Lymphoproliferative Syndrome

First Posted Date: 2012-08-27

Last Posted Date: 2019-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01672918

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy